Literature DB >> 2832316

Tumour necrosis factor beta (lymphotoxin) inhibits locomotion and stimulates the respiratory burst and degranulation of neutrophils.

A Ferrante1, M Nandoskar, E J Bates, D H Goh, L J Beard.   

Abstract

The data presented here demonstrate that recombinant human tumour necrosis factor beta (rHuTNF beta; lymphotoxin) is a neutrophil modulator. The lymphokine inhibited the locomotion of neutrophils and augmented the neutrophil oxygen-dependent respiratory burst in response to N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) and phorbol myristate acetate (PMA), as measured by their capacity to produce chemiluminescence, H2O2 and superoxide. The effects on the respiratory burst occurred at a tenth of the concentration of TNF beta required to inhibit locomotion. After incubation with TNF beta, the neutrophils could be washed without any reduction in their capacity to show augmented responses. The TNF beta enhanced granule enzyme (lysozyme and beta-glucuronidase) release of neutrophils stimulated with cytochalasin B-FMLP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832316      PMCID: PMC1454754     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes.

Authors:  R D Nelson; P G Quie; R L Simmons
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Human leukocyte acid hydrolases: characterization of eleven lysosomal enzymes and study of reaction conditions for their automated analysis.

Authors:  E H Kolodny; R A Mumford
Journal:  Clin Chim Acta       Date:  1976-07-15       Impact factor: 3.786

3.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent.

Authors:  B M Babior; R S Kipnes; J T Curnutte
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

4.  Early decay of human neutrophil chemotactic responsiveness following isolation from peripheral blood.

Authors:  A Ferrante; L J Beard; Y H Thong
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

5.  Conditioned medium from stimulated mononuclear leukocytes augments human neutrophil-mediated killing of a virulent Acanthamoeba sp.

Authors:  A Ferrante; T J Abell
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

6.  Human mononuclear cells exposed to staphylococci rapidly produce an inhibitor of neutrophil chemotaxis.

Authors:  H Donabedian
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

7.  Cellular origin of human lymphotoxin and its purification.

Authors:  S Pichyangkul; J E Miller; S Waldrop; A Khan
Journal:  Clin Immunol Immunopathol       Date:  1985-04

8.  Suppression of immunological responses in mice by treatment with amphotericin B.

Authors:  A Ferrante; B Rowan-Kelly; Y H Thong
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

9.  Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

Authors:  M R Shalaby; B B Aggarwal; E Rinderknecht; L P Svedersky; B S Finkle; M A Palladino
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

10.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

Authors:  G E Nedwin; L P Svedersky; T S Bringman; M A Palladino; D V Goeddel
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

View more
  20 in total

1.  Re-evaluation of the chemotactic activity of tumour necrosis factor for monocytes.

Authors:  J M Wang; S Walter; A Mantovani
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

2.  Neutrophil-mediated cartilage injury in vitro is enhanced by tumour necrosis factor alpha.

Authors:  I C Kowanko; E J Bates; A Ferrante
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  T cell-dependent chronic neutrophilia during mycobacterial infections.

Authors:  R Appelberg; M T Silva
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

4.  Production of lymphotoxin by isolated human tonsillar B lymphocytes and B lymphocyte cell lines.

Authors:  S S Sung; L K Jung; J A Walters; E W Jeffes; G A Granger; S M Fu
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

5.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis.

Authors:  H R Alexander; B C Sheppard; J C Jensen; H N Langstein; C M Buresh; D Venzon; E C Walker; D L Fraker; M C Stovroff; J A Norton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  Chemotactic activity of lymphotoxin and tumour necrosis factor alpha for human neutrophils.

Authors:  I Newman; P C Wilkinson
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

7.  Staphylococcus aureus-stimulated mononuclear leucocyte-conditioned medium increases the neutrophil bactericidal activity, and augments oxygen radical production and degranulation in response to the bacteria.

Authors:  A Ferrante; D P Harvey; E J Bates
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

8.  Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha.

Authors:  B Meier; H H Radeke; S Selle; M Younes; H Sies; K Resch; G G Habermehl
Journal:  Biochem J       Date:  1989-10-15       Impact factor: 3.857

9.  Decreased luminol-dependent chemiluminescence response of neutrophils to recombinant human tumour necrosis factor in patients with gastric cancer.

Authors:  I A Schepetkin; N V Cherdyntseva; E V Borunov; I L Skutina; S A Naumov
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  A role for intestinal T lymphocytes in bronchus mucosal immunity.

Authors:  F J Wallace; A W Cripps; R L Clancy; A J Husband; C S Witt
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.